KR101524636B1 - 원핵 세포로부터의 재조합 ｎ-글리코실화 단백질 - Google Patents

원핵 세포로부터의 재조합 ｎ-글리코실화 단백질 Download PDF

Info

Publication number
KR101524636B1
KR101524636B1 KR1020147001671A KR20147001671A KR101524636B1 KR 101524636 B1 KR101524636 B1 KR 101524636B1 KR 1020147001671 A KR1020147001671 A KR 1020147001671A KR 20147001671 A KR20147001671 A KR 20147001671A KR 101524636 B1 KR101524636 B1 KR 101524636B1
Authority
KR
South Korea
Prior art keywords
protein
glycosylation
ala
lys
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020147001671A
Other languages
English (en)
Korean (ko)
Other versions
KR20140019482A (ko
Inventor
마르쿠스 아에비
미하엘 코바리크
우메시 아후자
Original Assignee
에테하 취리히
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에테하 취리히 filed Critical 에테하 취리히
Publication of KR20140019482A publication Critical patent/KR20140019482A/ko
Application granted granted Critical
Publication of KR101524636B1 publication Critical patent/KR101524636B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/205—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/25—Shigella (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/01—Hexosyltransferases (2.4.1)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/034—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the periplasmic space of Gram negative bacteria as a soluble protein, i.e. signal sequence should be cleaved
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020147001671A 2005-05-11 2006-05-10 원핵 세포로부터의 재조합 ｎ-글리코실화 단백질 Active KR101524636B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05010276 2005-05-11
EP05010276.3 2005-05-11
PCT/EP2006/004397 WO2006119987A2 (en) 2005-05-11 2006-05-10 Recombinant n-glycosylated proteins from procaryotic cells

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020077028970A Division KR101408653B1 (ko) 2005-05-11 2006-05-10 원핵 세포로부터의 재조합 ｎ-글리코실화 단백질

Publications (2)

Publication Number Publication Date
KR20140019482A KR20140019482A (ko) 2014-02-14
KR101524636B1 true KR101524636B1 (ko) 2015-06-03

Family

ID=37396912

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020147001671A Active KR101524636B1 (ko) 2005-05-11 2006-05-10 원핵 세포로부터의 재조합 ｎ-글리코실화 단백질
KR1020077028970A Active KR101408653B1 (ko) 2005-05-11 2006-05-10 원핵 세포로부터의 재조합 ｎ-글리코실화 단백질

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020077028970A Active KR101408653B1 (ko) 2005-05-11 2006-05-10 원핵 세포로부터의 재조합 ｎ-글리코실화 단백질

Country Status (19)

Country Link
US (3) US8753864B2 (enExample)
EP (3) EP2853600B1 (enExample)
JP (3) JP5356807B2 (enExample)
KR (2) KR101524636B1 (enExample)
CN (2) CN101360831B (enExample)
AT (1) ATE483027T1 (enExample)
AU (1) AU2006245969B8 (enExample)
CA (1) CA2607595C (enExample)
CY (1) CY1116285T1 (enExample)
DE (1) DE602006017207D1 (enExample)
DK (2) DK2311972T3 (enExample)
ES (3) ES2535084T3 (enExample)
HK (1) HK1205193A1 (enExample)
HR (1) HRP20150312T1 (enExample)
IL (2) IL187293A (enExample)
PL (1) PL2311972T3 (enExample)
PT (2) PT1888761E (enExample)
SI (1) SI2311972T1 (enExample)
WO (1) WO2006119987A2 (enExample)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
CA2477794C (en) 2002-03-07 2013-08-20 Eidgenoessische Technische Hochschule Zuerich System and method for the production of recombinant glycosylated proteins in a prokaryotic host
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
SG155777A1 (en) 2003-04-09 2009-10-29 Neose Technologies Inc Glycopegylation methods and proteins/peptides produced by the methods
WO2005012484A2 (en) 2003-07-25 2005-02-10 Neose Technologies, Inc. Antibody-toxin conjugates
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
JP5743368B2 (ja) 2004-01-08 2015-07-01 ラショファーム ゲーエムベーハー ペプチドのｏ結合型グリコシル化
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
AU2005251676B2 (en) * 2004-03-03 2011-09-29 Revance Therapeutics, Inc. Compositions and methods for topical diagnostic and therapeutic transport
US20080300173A1 (en) 2004-07-13 2008-12-04 Defrees Shawn Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1]
HUE026826T2 (en) 2004-10-29 2016-07-28 Ratiopharm Gmbh Modeling and glycopegylation of fibroblast growth factor (FGF)
US9029331B2 (en) 2005-01-10 2015-05-12 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
BRPI0608249A2 (pt) * 2005-03-03 2009-12-08 Revance Therapeutics Inc formulação, método para aplicação tópica e kit para distribuição transdérmica de toxina botulìnica
EP1871795A4 (en) 2005-04-08 2010-03-31 Biogenerix Ag COMPOSITIONS AND METHOD FOR PRODUCING GLYCOSYLATION MUTANTS OF A PROTEASE-RESISTANT HUMAN GROWTH HORMONE
EP1891231A4 (en) 2005-05-25 2011-06-22 Novo Nordisk As GLYCOPEGYLATED FACTOR IX
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
US20080248959A1 (en) 2006-07-21 2008-10-09 Neose Technologies, Inc. Glycosylation of peptides via o-linked glycosylation sequences
JP2010505874A (ja) 2006-10-03 2010-02-25 ノヴォ ノルディスク アー／エス ポリペプチドコンジュゲートの精製方法
RS52845B (sr) 2007-04-03 2013-12-31 Biogenerix Ag Postupci tretmana korišćenjem glikopegiliranog g-csf
JP5876649B2 (ja) 2007-06-12 2016-03-02 ラツィオファルム ゲーエムベーハーｒａｔｉｏｐｈａｒｍ ＧｍｂＨ ヌクレオチド糖の改良製造法
US8999668B2 (en) 2008-01-03 2015-04-07 Cornell Research Foundation, Inc. Glycosylated protein expression in prokaryotes
EP2242505A4 (en) * 2008-01-08 2012-03-07 Biogenerix Ag GLYCOCONJUGATION OF POLYPEPTIDES USING OLIGOSACCHARYLTRANSFERASES
HRP20181259T1 (hr) * 2008-02-20 2018-10-05 Glaxosmithkline Biologicals S.A. Biokonjugati načinjeni iz rekombinantnih n-glikoziliranih proteina iz prokariotskih stanica
ES2476690T3 (es) 2008-02-27 2014-07-15 Novo Nordisk A/S Moléculas conjugadas del Factor VIII
PL2411503T3 (pl) * 2009-03-27 2018-01-31 Eidgenoessische Technische Hochschule Zuerich Salmonella enterica prezentująca n-glikan z c. jejuni lub jego pochodne
AU2010322454B2 (en) * 2009-11-19 2016-05-19 Glaxosmithkline Biologicals S.A. Biosynthetic system that produces immunogenic polysaccharides in prokaryotic cells
JP5925699B2 (ja) 2010-02-11 2016-05-25 ザ・ガバナーズ・オブ・ザ・ユニバーシティー・オブ・アルバータ Ｎ結合型グリカン化合物
ES2844596T3 (es) * 2010-05-06 2021-07-22 Glaxosmithkline Biologicals Sa Vacunas de bioconjugados de bacterias grampositivas capsulares
JP2013539963A (ja) * 2010-09-03 2013-10-31 ザ ガバナーズ オブ ザ ユニバーシティ オブ アルバータ 複数のｎ結合型グリコシル化シークオンを含んでいるペプチド
AU2012306345A1 (en) 2011-09-06 2014-03-20 Glycovaxyn Ag Bioconjugate vaccines made in prokaryotic cells
SG11201503308XA (en) 2012-11-07 2015-05-28 Glycovaxyn Ag PRODUCTION OF RECOMBINANT VACCINE IN <i>E. COLI</i> BY ENZYMATIC CONJUGATION
BR112015014991B1 (pt) 2013-01-17 2024-01-23 Janssen Pharmaceuticals, Inc Anticorpo específico para e. coli mdr, plasmídeo, cassete de expressão, célula hospedeira, método de produção do anticorpo, método para identificar um anticorpo candidato, preparação farmacêutica e de diagnóstico, epítopo, imunogênio e ácido nucleico utilizados
CA2923957C (en) 2013-01-18 2021-08-31 London School Of Hygiene And Tropical Medicine Glycosylation method
GB201301085D0 (en) 2013-01-22 2013-03-06 London School Hygiene & Tropical Medicine Glycoconjugate Vaccine
BR112015022849B1 (pt) * 2013-03-15 2020-02-18 Asieris Pharmaceutical Technologies Co., Ltd. Sais de adição de base de nitroxolina, usos e processo para preparação dos mesmos, bem como seu cristal, composição farmacêutica e processo para preparação da mesma
EP2991675B1 (en) * 2013-04-05 2019-07-24 The Governors of the University of Alberta Campylobacter vaccine
US11220676B2 (en) * 2013-10-11 2022-01-11 Glaxosmithkline Biological Sa Methods of host cell modification
EA035991B9 (ru) 2014-02-24 2020-10-21 Глаксосмитклайн Байолоджикалс С.А. Новый полисахарид и его применения
SI3131577T1 (sl) 2014-04-17 2020-08-31 Glaxosmithkline Biologicals S.A. Modificirane gostiljske celice in uporabe le-teh
SG11201700325SA (en) 2014-08-08 2017-02-27 Glycovaxyn Ag Modified host cells and hybrid oligosaccharides for use in bioconjugate production
SI3240895T1 (sl) * 2014-12-30 2022-04-29 Glaxosmithkline Biologicals S.A. Sestavki in postopki za glikozilacijo proteinov
TWI715617B (zh) 2015-08-24 2021-01-11 比利時商葛蘭素史密斯克藍生物品公司 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物
GB201518668D0 (en) * 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Immunogenic Comosition
WO2017117539A1 (en) 2015-12-30 2017-07-06 Northwestern University Cell-free glycoprotein synthesis (cfgps) in prokaryotic cell lysates enriched with components for glycosylation
GB201610599D0 (en) 2016-06-17 2016-08-03 Glaxosmithkline Biologicals Sa Immunogenic Composition
US10829795B2 (en) 2016-07-14 2020-11-10 Northwestern University Method for rapid in vitro synthesis of glycoproteins via recombinant production of N-glycosylated proteins in prokaryotic cell lysates
AR109621A1 (es) 2016-10-24 2018-12-26 Janssen Pharmaceuticals Inc Formulaciones de vacunas contra glucoconjugados de expec
EP3573654A4 (en) * 2017-01-27 2020-11-25 University of Florida Research Foundation, Incorporated FOOD SAFETY VACCINE TO CONTROL SALMONELLA ENTERICA AND REDUCE CAMPYLOBACTER IN POULTRY
GB201712678D0 (en) 2017-08-07 2017-09-20 Glaxosmithkline Biologicals Sa Process for the manipulation of nucleic acids
US11898187B2 (en) 2017-08-15 2024-02-13 Northwestern University Protein glycosylation sites by rapid expression and characterization of N-glycosyltransferases
GB201721576D0 (en) 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa Hla antigens and glycoconjugates thereof
GB201721582D0 (en) * 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa S aureus antigens and immunogenic compositions
TW201946650A (zh) 2018-03-12 2019-12-16 美商詹森藥物公司 針對腹內感染之疫苗
US11530432B2 (en) 2018-03-19 2022-12-20 Northwestern University Compositions and methods for rapid in vitro synthesis of bioconjugate vaccines in vitro via production and N-glycosylation of protein carriers in detoxified prokaryotic cell lysates
US11725224B2 (en) 2018-04-16 2023-08-15 Northwestern University Methods for co-activating in vitro non-standard amino acid (nsAA) incorporation and glycosylation in crude cell lysates
WO2020072127A2 (en) 2018-08-03 2020-04-09 Northwestern University On demand, portable, cell-free molecular sensing platform
WO2020120569A2 (en) 2018-12-12 2020-06-18 Glaxosmithkline Biologicals Sa Modified carrier proteins for o-linked glycosylation
US12404533B2 (en) 2019-01-11 2025-09-02 Northwestern University Bioconjugate vaccines' synthesis in prokaryotic cell lysates
US12325884B2 (en) 2019-03-04 2025-06-10 Northwestern University Riboswitch-based fluoride sensing in cell-free extract
IL286467B1 (en) 2019-03-18 2025-10-01 Janssen Pharmaceuticals Inc Methods for producing bioconjugates of E. COLI O-antigen polysaccharides, preparations thereof and methods for using them
MY205586A (en) * 2019-03-18 2024-10-28 Janssen Pharmaceuticals Inc Bioconjugates of e. coli o-antigen polysaccharides, methods of production thereof, and methods of use thereof
EP3757217A1 (en) 2019-06-27 2020-12-30 GlaxoSmithKline Biologicals S.A. Methods for protein purification
EP3770269A1 (en) * 2019-07-23 2021-01-27 GlaxoSmithKline Biologicals S.A. Quantification of bioconjugate glycosylation
EP3777884A1 (en) 2019-08-15 2021-02-17 GlaxoSmithKline Biologicals S.A. Immunogenic composition
US12226410B2 (en) 2019-10-18 2025-02-18 Northwestern University Methods for enhancing cellular clearance of pathological molecules via activation of the cellular protein ykt6
WO2021144369A1 (en) 2020-01-16 2021-07-22 Janssen Pharmaceuticals, Inc. Fimh mutant, compositions therewith and use thereof
CA3185719A1 (en) 2020-06-18 2021-12-23 Glaxosmithkline Biologicals Sa Shigella-tetravalent (shigella4v) bioconjugate
US20230293657A1 (en) 2020-06-25 2023-09-21 Glaxosmithkline Biologicals Sa Vaccine
KR20230043157A (ko) 2020-09-17 2023-03-30 얀센 파마슈티칼즈, 인코포레이티드 다가 백신 조성물 및 이의 용도
TW202241929A (zh) 2021-01-12 2022-11-01 美商詹森藥物公司 ＦｉｍＨ突變體、其組成物及其用途
CA3215752A1 (en) 2021-04-01 2022-10-06 Janssen Pharmaceuticals, Inc. Production of e. coli o18 bioconjugates
EP4452308A1 (en) 2021-12-22 2024-10-30 GlaxoSmithKline Biologicals S.A. Vaccine
GB202302579D0 (en) 2023-02-23 2023-04-12 Glaxosmithkline Biologicals Sa Immunogenic composition
WO2025032534A2 (en) 2023-08-09 2025-02-13 Glaxosmithkline Biologicals Sa Modified proteins
WO2025032535A2 (en) 2023-08-09 2025-02-13 Glaxosmithkline Biologicals Sa Modified proteins
WO2025172892A1 (en) 2024-02-16 2025-08-21 Glaxosmithkline Biologicals Sa Modified proteins and methods

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002074687A1 (de) * 2001-03-20 2002-09-26 Messer Griesheim Gmbh Verfahren zum regenerieren von schwefelsäure aus schwefelhaltigen stoffen
WO2004013151A2 (en) * 2002-08-01 2004-02-12 National Research Council Of Canada Campylobacter glycans and glycopeptides

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0170204B1 (de) 1984-08-01 1991-09-25 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Neue genetische Sequenzen, die durch sie codierten Interferon-Peptide vom Typ I und diese sie produzierende Organismen
US5643758A (en) 1987-03-10 1997-07-01 New England Biolabs, Inc. Production and purification of a protein fused to a binding protein
EP0726318A1 (en) 1993-05-14 1996-08-14 The Upjohn Company An acceptor polypeptide for an N-acetylgalactosaminyltransferase
US6503744B1 (en) 1999-02-01 2003-01-07 National Research Council Of Canada Campylobacter glycosyltransferases for biosynthesis of gangliosides and ganglioside mimics
CA2363297C (en) 1999-03-02 2011-08-09 Michael J. Betenbaugh Engineering intracellular sialylation pathways
US20020127219A1 (en) * 1999-12-30 2002-09-12 Okkels Jens Sigurd Lysosomal enzymes and lysosomal enzyme activators
NZ522320A (en) 2000-05-12 2007-03-30 Neose Technologies Inc In vitro modification of glycosylation patterns of recombinant glycopeptides
EP2267135A3 (en) 2000-06-30 2011-09-14 Vib Vzw Protein glycosylation modification in pichia pastoris
CA2477794C (en) * 2002-03-07 2013-08-20 Eidgenoessische Technische Hochschule Zuerich System and method for the production of recombinant glycosylated proteins in a prokaryotic host
KR20130101592A (ko) 2002-03-07 2013-09-13 아이드게노쉬쉐 테흐니쉐 호흐슐레 쥬리히 원핵 숙주에서의 재조합 글리코실화 단백질 생산 방법 및 생산계

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002074687A1 (de) * 2001-03-20 2002-09-26 Messer Griesheim Gmbh Verfahren zum regenerieren von schwefelsäure aus schwefelhaltigen stoffen
WO2004013151A2 (en) * 2002-08-01 2004-02-12 National Research Council Of Canada Campylobacter glycans and glycopeptides
WO2004013151A3 (en) 2002-08-01 2004-07-01 Ca Nat Research Council Campylobacter glycans and glycopeptides

Also Published As

Publication number Publication date
HK1205193A1 (en) 2015-12-11
IL226857A (en) 2017-08-31
WO2006119987A2 (en) 2006-11-16
AU2006245969B8 (en) 2011-08-25
JP2008539743A (ja) 2008-11-20
CN103396478A (zh) 2013-11-20
CY1116285T1 (el) 2017-02-08
EP1888761B1 (en) 2010-09-29
ATE483027T1 (de) 2010-10-15
JP5687637B2 (ja) 2015-03-18
KR101408653B1 (ko) 2014-06-17
JP5827303B2 (ja) 2015-12-02
US20140323700A1 (en) 2014-10-30
CN101360831B (zh) 2013-07-10
ES2353814T3 (es) 2011-03-07
EP2311972A1 (en) 2011-04-20
PT1888761E (pt) 2011-01-03
US8753864B2 (en) 2014-06-17
HRP20150312T1 (hr) 2015-07-31
IL187293A (en) 2013-06-27
HK1113588A1 (en) 2008-10-10
EP2853600B1 (en) 2018-09-19
CA2607595A1 (en) 2006-11-16
ES2703061T3 (es) 2019-03-06
SI2311972T1 (sl) 2015-08-31
HK1156983A1 (en) 2016-11-25
KR20140019482A (ko) 2014-02-14
IL226857A0 (en) 2013-07-31
US20100062484A1 (en) 2010-03-11
US9551019B2 (en) 2017-01-24
CA2607595C (en) 2018-11-27
WO2006119987A3 (en) 2007-03-08
JP2012100678A (ja) 2012-05-31
EP1888761A2 (en) 2008-02-20
PL2311972T3 (pl) 2015-08-31
JP5356807B2 (ja) 2013-12-04
JP2014042533A (ja) 2014-03-13
IL187293A0 (en) 2008-04-13
EP2853600A1 (en) 2015-04-01
DK2311972T3 (en) 2015-04-27
PT2311972E (pt) 2015-05-13
CN101360831A (zh) 2009-02-04
CN103396478B (zh) 2016-09-28
AU2006245969A1 (en) 2006-11-16
KR20080048990A (ko) 2008-06-03
US20160326563A1 (en) 2016-11-10
DK1888761T3 (da) 2010-11-01
ES2535084T3 (es) 2015-05-05
DE602006017207D1 (de) 2010-11-11
EP2311972B1 (en) 2015-01-21
AU2006245969B2 (en) 2011-06-02

Similar Documents

Publication Publication Date Title
KR101524636B1 (ko) 원핵 세포로부터의 재조합 ｎ-글리코실화 단백질
US11944675B2 (en) Bioconjugates made from recombinant N-glycosylated proteins from procaryotic cells
AU2011218682B2 (en) Recombinant N-glycosylated proteins from procaryotic cells
HK1156983B (en) Recombinant n-glycosylated proteins from procaryotic cells
HK1113588B (en) Recombinant n-glycosylated proteins from procaryotic cells
AU2014200938A1 (en) Recombinant n-glycosylated proteins from procaryotic cells

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20140121

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20140220

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20140313

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20141027

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20150423

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20150526

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20150527

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20180329

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20180329

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20190327

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20190327

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20200324

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20210426

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20240424

Start annual number: 10

End annual number: 10